Next Thursday's event brings together four London-listed companies with huge potential.
eg Solutions (LON:EGS), e-Therapeutics (LON:ETX), Motif Bio (LON:MTFB) and Amphion Innovations (LON:AMP) have plenty of exciting near term newsflow. Make sure you don't miss out on the event on September 24 by securing your place HERE.
eg Solutions is a leading enterprise software optimisation software company, specialising in back office space.
Last month eg Solutions told investors that trading was in line with expectations for the six months to July 31 as its order book over the period increased to £15.5 million.
The company will be presenting just one day after it launches two new products - eg forecasting and eg mobile. Chief executive Elizabeth Gooch will be here to explain how these two products will help to drive growth going forwards.
e-Therapeutics is a drug discovery and development company based in Oxford and Newcastle. It has a clinical pipeline of two drugs, ETS2101 which is in phase I trials for cancer and ERS6103 which is in phase II development for depression.
The 2015 calendar year has been a period of much progress for e-Therapeutics with the company most recently revealing that it has received approval from the US Food and Drug Administration for an application to extend its phase Ib trials for ETS2101 in the United States.
CEO Malcolm Young will be at the conference to present the investment proposition to followers of the company.
Motif Bio is a clinical stage biopharmaceutical company which specialises in developing antibiotics designed to be effective against serious and life-threatening diseases.
Back in July the company raised £22 million as it endeavours to push forwards with its phase III trials on its Icplarim antibiotic - a product designed to be effective against multi-drug resistant bacteria.
Since its flotation on AIM back in April, Motif Bio's shares have almost doubled in value as its Icplarim project has progressed. Chief Executive Graeme Lumsden will be updating investors on where this project currently sits and the long term prospects for the company.
Amphion invests in companies in the medical and technology sectors and currently has significant holdings in seven companies - one of which is Motif Bio.
Other companies within Amphion's portfolio include Kromek Group, WellGen and m2m imaging. Amphion also owns 100% of DataTern - an entity focussed on the development of intellectual property.
Each partner company is chosen with the goal of achieving an exit valuation of $100 million and Chief Executive Richard Morgan will be on hand to give an update on the current state of the portfolio.
Please join us at 5:45pm to allow for a prompt 6pm start. Each company has 20 minutes to give a short presentation and then 10 minutes Q&A. This will be followed by the 'Champagne Raffle' where six guests will win a bottle each.
The event will be rounded off with a drinks reception with canapés.